		NT OF HEALTH AND HUMAN			
DISTRICT ADDRESS AND PHO		0	ATE(S) OF INSPECTION		
	entral Expressway, Suite 300		5/23/2017-6/2/2017*		
Dallas, TX 7			EINUMBER 3012053582		
(214)253-520	14)253-5200 Fax:(214)253-5314		······································		
NAME AND TITLE OF INDIVIDU	AL TO WHOM REPORT ISSUED				
Stephen J. R	hoades , Director of	Quality			
FIRM NAME		STREET ADDRESS	the second s		
QuVa Pharma,	Inc.	1075 W Park One Dr Ste 100			
CITY, STATE, ZIP CODE, COUR			te batter distance in the bar		
Sugar Land,	TX 77478-2576	Outsourcir	Outsourcing Facility		
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.					
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.					
Specifically,					
On 05/23/2017, we observed three out of $(b)(4)$ of that day's production technicians resting their elbows on the front areas of multiple laminar airflow hoods while producing sterile drug products.					
This behavior was observed during the production of:					
1. Ropivacaine HCL PF 0.2%, 2mg/ml, Lot #10003990, NS 200 mL in 250 mL, Cassette (400 mg), in clean room ^{(b)(4)} inside laminar airflow hood #3, serial (b) (4) produced by technician one.					
2. Fentanyl Citrate, PF 2mco/mL/ Bupivacaine HCL PF 0.125% in 0.9% Sodium Chloride, 250 mL, Lot #10003982, in clean room inside laminar airflow hood #3, serial(b)(4) produced by technician two.					
3. Magnesium Sulfate PF 2g added to 5% Dextrose, 50 mL, Lot #10004066, in clean room ^{(b) (4)} inside biosafety cabinet #2, serial (b) (4) produced by technician three.					
*DATES OF INSPECTION 5/23/2017(Tue),5/24/2017(Wed),5/25/2017(Thu),5/26/2017(Fri),5/30/2017(Tue),5/31/2017(Wed),6/01/2 017(Thu),6/02/2017(Fri)					
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Jason R Caballero, I Shatina R Alridge, I		4/2/20 X Jason R Caballero Jason R Caballero Investigetur Sped by Jason R. Caballero 45	DATE ISSUED 6/2/2017	
FORM FDA 483 (69/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBS	ERVATIONS	PAGE 1 OF 2 PAGES	

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION 5/23/2017-6/2/2017*				
4040 North Central Expressway, Suite 300 Dallas, TX 75204	FEI NUMBER				
(214)253-5200 Fax: (214)253-5314	3012053582				
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED					
Stephen J. Rhoades , Director of Quality					
FIRM NAME	STREET ADDRESS 1075 W Park One Dr Ste 100				
QuVa Pharma, Inc.	TYPE ESTABLISHMENT INSPECTED				
Sugar Land, TX 77478-2576	Outsourcing Facility				
Shatina R Alridge Investigator Signed by: Shatina R. Artige -5					
SEE REVERSE OF THIS PAGE Jason R Caballero, Investiga Shatina R Alridge, Investiga					
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INS	PECTIONAL OBSERVATIONS PAGE 2 OF 2 PAGES				